Immune response to mRNA‐based COVID‐19 booster vaccination in people living with HIV

Abstract

AbstractObjectivesOur objective was to assess immune responses and their influencing factors in people living with HIV after messenger RNA (mRNA)‐based COVID‐19 booster vaccination (third dose).MethodsThis was a retrospective cohort study of people living with HIV who received booster vaccination with BNT‐162b2 or mRNA‐1273 between October 2021 and January 2022. We assessed anti‐spike receptor‐binding domain (RBD) immunoglobulin G (IgG), virus neutralizing activity (VNA) titres reported as 100% inhibitory dilution (ID100), and T‐cell response (using interferon‐gamma‐release‐assay [IGRA]) at baseline and quarterly follow‐up visits. Patients with reported COVID‐19 during follow‐up were excluded. Predictors of serological immune response were analyzed using multivariate regression models.ResultsOf 84 people living with HIV who received an mRNA‐based booster vaccination, 76 were eligible for analysis. Participants were on effective antiretroviral therapy (ART) and had a median of 670 CD4+cells/μL (interquartile range [IQR] 540–850). Following booster vaccination, median anti‐spike RBD IgG increased by 705.2 binding antibody units per millilitre (BAU/mL) and median VNA titres increased by 1000 ID100 at the follow‐up assessment (median 13 weeks later). Multivariate regression revealed that time since second vaccination was a predictor of stronger serological responses (p < 0.0001). No association was found for other factors, including CD4+ status, choice of mRNA vaccine, or concomitant influenza vaccination. In total, 45 patients (59%) had a reactive baseline IGRA, of whom two lost reactivity during follow‐up. Of 31 patients (41%) with non‐reactive baseline IGRA, 17 (55%) converted to reactive and seven (23%) remained unchanged following booster vaccination.ConclusionsPeople living with HIV with ≥500 CD4+cells/μL showed favourable immune responses to mRNA‐based COVID‐19 booster vaccination. A longer time (up to 29 weeks) since second vaccination was associated with higher serological responses, whereas choice of mRNA vaccine or concomitant influenza vaccination had no impact.